Literature DB >> 16299156

Linezolid induced toxic optic neuropathy.

K Kulkarni, L V Del Priore.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299156      PMCID: PMC1773000          DOI: 10.1136/bjo.2005.074237

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  12 in total

1.  Linezolid-induced neuropathy.

Authors:  Carmela E Corallo; Amalie E Paull
Journal:  Med J Aust       Date:  2002-09-16       Impact factor: 7.738

2.  Severe bilateral optic neuritis associated with prolonged linezolid therapy.

Authors:  Frédéric Frippiat; Christelle Bergiers; Claire Michel; Jean-Pierre Dujardin; Geneviève Derue
Journal:  J Antimicrob Chemother       Date:  2004-04-29       Impact factor: 5.790

3.  Linezolid-induced neuropathy.

Authors:  L Legout; E Senneville; J J Gomel; Y Yazdanpanah; Y Mouton
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

4.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

Authors:  D L Shinabarger; K R Marotti; R W Murray; A H Lin; E P Melchior; S M Swaney; D S Dunyak; W F Demyan; J M Buysse
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Multi-system Infection with Nocardia farcinica-therapy with linezolid and minocycline.

Authors:  K E Lewis; P Ebden; S L Wooster; J Rees; G A J Harrison
Journal:  J Infect       Date:  2003-04       Impact factor: 6.072

6.  Linezolid-associated peripheral neuropathy.

Authors:  Jennifer P Rho; Irene G Sia; Brian A Crum; Mark B Dekutoski; Robert T Trousdale
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

Review 7.  Peripheral neuropathy associated with prolonged use of linezolid.

Authors:  Adam M Bressler; Shanta M Zimmer; Jane L Gilmore; Jyoti Somani
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

8.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Authors:  Mary C Birmingham; Craig R Rayner; Alison K Meagher; Susan M Flavin; Donald H Batts; Jerome J Schentag
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

9.  Mechanisms for linezolid-induced anemia and thrombocytopenia.

Authors:  Wendy B Bernstein; Richard F Trotta; James T Rector; Jeffery A Tjaden; Anthony J Barile
Journal:  Ann Pharmacother       Date:  2003-04       Impact factor: 3.154

10.  Linezolid-associated toxic optic neuropathy: a report of 2 cases.

Authors:  Elsie Lee; Susanne Burger; Jilan Shah; Christine Melton; Michael Mullen; Floyd Warren; Robert Press
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079

View more
  6 in total

Review 1.  Linezolid-induced optic neuropathy: a mitochondrial disorder?

Authors:  M Javaheri; R N Khurana; T M O'hearn; M M Lai; A A Sadun
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

2.  Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis.

Authors:  Katsuji Kiuchi; Miki Miyashiro; Chiemi Kitagawa; Sanae Wada
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

Review 3.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

Review 4.  Are we pharmacovigilant enough in ophthalmic practice?

Authors:  Ashok Dubey; Shailendra S Handu
Journal:  Indian J Ophthalmol       Date:  2013-05       Impact factor: 1.848

5.  Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.

Authors:  Salil Mehta; Mrinalini Das; Chinmay Laxmeshwar; Sylvie Jonckheere; Sein Sein Thi; Petros Isaakidis
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

6.  Linezolid-associated optic neuropathy in a pediatric patient with Mycobacterium nonchromogenicum: A case report.

Authors:  Napoleón González Saldaña; Diego Mauricio Galvis Trujillo; Ana Maria Borbolla Pertierra; Ana Ivette Mondragón Pineda; Hugo Juárez Olguín
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.